ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Moderna Inc

Moderna Inc (MRNA)

104.26
0.41
(0.39%)
Closed March 18 04:00PM
104.26
0.00
( 0.00% )
Pre Market: 07:35AM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

MRNA News

Official News Only

MRNA Discussion

View Posts
Vexari Vexari 11 hours ago
What does it mean
😎 1
Vexari Vexari 3 days ago
Moderna and clickbait

As usual

Interesting perspective
💤 1 💩 1 💯 1 😎 1 🤡 1 🤮 2
axelvento axelvento 5 days ago
There's a big need for RSV vaccines. Even with two rivals already on the market, mRNA-1345 should be quite competitive, with its solid efficacy and prefilled syringe, which makes it easier for pharmacists and doctors.

Moderna also plans to file for FDA approval of its seasonal flu vaccine mRNA-1010 in 2024
👍️0
axelvento axelvento 6 days ago
Melanoma
Renal Cell Carcinoma
Carcinoma, Squamous Cell
Bladder Cancer
Non-small Cell Lung Cancer
https://clinicaltrials.gov/search?cond=mRNA-4157%20V940
👍️0
axelvento axelvento 7 days ago
write it in your brain----- $MRNA multibager$
👍️ 1 💩 1 🤡 1
axelvento axelvento 7 days ago
all bullshit
👍️ 1 💩 1 🤡 1
spartex spartex 1 week ago
First Breakout of what??

Well, I found it from IBD link (via yahoo) below a little text, as I have the WSJ, Barron's and IBD digital package. The 1 year chart shows a 52 week high of $163, so I have no idea why $111 is "Moderna Nears its first breakout in over a year"........lol click bait as usual.

Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test

ALLISON GATLIN04:24 PM ET 03/11/2024
Moderna (MRNA) stock surged Monday — nearing its first breakout in over a year — after launching a third study of its Merck (MRK)-partnered cancer vaccine.

https://finance.yahoo.com/m/c88bcc75-936e-34b7-8357-2136d66b53a9/moderna-nears-its-first.html
👍️0
axelvento axelvento 1 week ago
new- https://classic.clinicaltrials.gov/ct2/show/NCT06295809?cond=mRNA-4157%2FV940&draw=2&rank=3
👍️0
axelvento axelvento 1 week ago
CSCC is the second-most common form of skin cancer in the U.S.

Merck's immunotherapy Keytruda along with Moderna's MRNA-based vaccine are also being evaluated for the treatment of melanoma and non-small cell lung cancer

Analysts at Jefferies say this being the third late-stage study for the vaccine combination speaks to continued confidence in a broad program
👍️ 1
axelvento axelvento 1 week ago
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test

The companies will test a combination of the cancer vaccine and Merck's blockbuster cancer drug, Keytruda, in patients with cutaneous squamous cell carcinoma
👍️0
axelvento axelvento 1 week ago
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024 "updates coming soon"
👍️ 1
Vexari Vexari 1 week ago
Lets elaborate from this quote

As it relates to the topic

From which

One responded to

How is it
Just ain’t so Just curious
💤 1 💩 1 🤡 1
Mfinvest Mfinvest 1 week ago
“It ain’t what you don’t know that gets you into trouble. It’s what you know for sure that just ain’t so. “ – Mark Twain
👍️0
Vexari Vexari 1 week ago
Reality is the difference between

What is told

And what is known

How can this bridge

Be gapped

Nice
👍️0
wickw50 wickw50 1 week ago
pic.twitter.com/elPoTAFW9o— healthbot (@thehealthb0t) March 9, 2024
💩 1 🤡 1
axelvento axelvento 2 weeks ago
The RNA-catalyzed evolution of functional RNAs is thought to have been central to the early history of life on Earth and to the possibility of constructing RNA-based life in the laboratory

https://www.pnas.org/doi/10.1073/pnas.2321592121

https://gizmodo.com/rna-world-could-have-kickstarted-first-life-on-earth-1851310245
👍️0
axelvento axelvento 2 weeks ago
"Guinness World Records " Hypervaccinated’ man reportedly received 217 Covid jabs without side-effects

https://www.theguardian.com/society/2024/mar/06/hypervaccinated-man-217-covid-jabs-no-side-effects-germany
👍️0
axelvento axelvento 2 weeks ago
3 Reasons to Buy Moderna Stock

https://finance.yahoo.com/news/3-reasons-buy-moderna-stock-181000927.html
👍️0
axelvento axelvento 2 weeks ago
CDC panel mulls changes to RSV vaccine recommendation:
https://finance.yahoo.com/news/cdc-panel-mulls-changes-rsv-120000070.html
Moderna has submitted its vaccine for Food and Drug Administration approval, which is set to decide by mid-May. If approved, ACIP could recommend its use in June, Jefferies analyst Michael Yee wrote in a note to clients
👍️0
axelvento axelvento 3 weeks ago
Moderna spells out rare disease ambitions: 'We have a bunch of INDs planned'

https://endpts.com/moderna-spells-out-rare-disease-ambitions-we-have-a-bunch-of-inds-planned/
👍️0
axelvento axelvento 3 weeks ago
CDC Meeting on RSV Vaccines -this week

https://www.barrons.com/articles/gsk-moderna-stock-rsv-vaccines-26e5f86b
👍️0
axelvento axelvento 3 weeks ago
Seems to have all it takes......The trial met both its primary efficacy endpoints, with a vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p
👍️ 1
DewDiligence DewDiligence 3 weeks ago
Actually, ACIP doesn't care about convenience of administration. They care about efficacy and safety.
👍️ 1 💯 1
spartex spartex 3 weeks ago
Shares of Moderna slid 1.4% as HSBC downgraded the U.S. vaccine maker to "reduce" from "hold."
👍️0
axelvento axelvento 3 weeks ago
only moderna...... the only pre-filled syringe product available at the time of launch.
👍️0
DewDiligence DewDiligence 3 weeks ago
The issue is not whether ACIP includes mRNA-1345 on its agenda (it surely will if MRNA-1345 receives FDA approval), but rather what ACIP's recommendation will be. The CDC almost always rubber-stamps whatever ACIP recommends, which then becomes the standard practice of most US healthcare providers.
👍️0
Vexari Vexari 3 weeks ago
How does one know

This is real

Considering
💤 1 💩 1 🤡 1
axelvento axelvento 3 weeks ago
"I read this" The PDUFA (Prescription Drug User Fee Act) action date for mRNA-1345 is May 12, 2024, by which time the Company expects the U.S. FDA's response to its Biologics License Application (BLA). If the outcome is positive, the Company anticipates that the U.S. CDC Advisory Committee on Immunization Practices (ACIP) will include mRNA-1345 on the agenda of its June 26-28 meeting. Assuming that corresponding marketing authorizations would be granted as expected, the Company also plans to launch its RSV vaccine in Australia and Germany in 2024 and other markets in 2025 due to regulatory and tender timing.
👍️0
Vexari Vexari 3 weeks ago
Take a step back and listen to oneself

What does it actually mean

From a different

Perspective
💤 1 💩 1 🤡 1 🤮 1
DewDiligence DewDiligence 3 weeks ago
MRNA has a lot riding on ACIP’s recommendations for how often people should be boosted with RSV vaccines. ACIP meets in late June, and it will presumably make recommendations for mRNA-1345, assuming the FDA has approved it by then (PDUFA date 5/12/24).

If ACIP recommends biennial boosting with GSK’s and PFE’s RSV vaccines for the “at-risk” adult populations, but recommends annual boosting with MRNA’s mRNA-1345, that would be a pretty big blow to mRNA-1345’s commercial prospects. I’m not saying such an outcome is likely, but it is possible.
👍️0
axelvento axelvento 3 weeks ago
In the fall vaccination season, Moderna captured 48% of the COVID-19 retail market in the United States versus a 37% showing in 2022, closing the gap on Pfizer’s Comirnaty

Much of the call was focused on Moderna’s respiratory syncytial virus (RSV) vaccine, which is lined up for an FDA decision in May. The company appears poised to join a market competition with GSK’s Arexvy and Pfizer’s Abrysvo, which achieved 2023 sales of $1.5 billion and $890 million, respectively, in their first year on the market for people ages 60 and older.

The company sees the RSV market booming to $10 billion, with sales of between $6 billion to $8 billion in the older adult population.

https://www.fiercepharma.com/pharma/while-moderna-moving-covid-its-vaccine-gaining-share-pfizers-comirnaty
👍️0
axelvento axelvento 3 weeks ago
"it's written on the wall"The big news in Moderna's Q4 update was a surprise profit of $217 million, or $0.53 per share, based on generally accepted accounting principles (GAAP). The average analysts' estimate was for a Q4 loss of $0.90 per share.

Moderna also reported Q4 revenue of $2.8 billion, down from $5.1 billion in the prior-year period. However, this result was well above the consensus revenue estimate of $2.3 billion.

I don't think Moderna stock is a buy solely because of its Q4 results. My view is that risk-averse investors will be better off going with other stocks.

However, aggressive investors could find Moderna appealing right now. The company hopes to win U.S. regulatory approval for its respiratory syncytial virus (RSV) vaccine soon. It's also optimistic about filing for approval of seasonal flu vaccine mRNA-1010 this year. I predict Moderna's future will be brighter than its recent past.

https://www.fool.com/investing/2024/02/22/why-moderna-stock-is-jumping-today/
👍️0
DewDiligence DewDiligence 4 weeks ago
MRNA 4Q23 CC transcript:

https://finance.yahoo.com/news/moderna-inc-nasdaq-mrna-q4-173137188.html
👍️0
axelvento axelvento 4 weeks ago
Moderna CEO: 2024 is year of growth, with 2023 transition in rearview

https://www.modernatx.com/en-US/media-center/all-media/blogs/recapping-q4-earnings-report-and-fiscal-year-2023
👍️ 1
Vexari Vexari 4 weeks ago
The results are astonishing

What about the facts
💤 1 💩 1 🤡 1
DewDiligence DewDiligence 4 weeks ago
MRNA 4Q23 results—2024 outlook:

PR:
https://s29.q4cdn.com/435878511/files/doc_earnings/2023/q4/earnings-result/Q4-23-PR_Final.pdf

CC slides:
https://s29.q4cdn.com/435878511/files/doc_earnings/2023/q4/presentation/Moderna-4Q23-Earnings-Presentation-Final.pdf

MRNA reiterated 2024 guidance for: $4B of product sales (mostly COVID Spikevax, but including some contribution from mRNA-1345 RSV vaccine, which has a 5/12/24 PDUFA date and a planned ACIP panel in late June); and $4.5B in R&D expenses.
👍️0
Vexari Vexari 4 weeks ago
According to and how

Should such a magnificent feat

Be established
💩 1 🤡 1
axelvento axelvento 1 month ago
Moderna Expected to Beat Earnings Estimates
👍️ 1
axelvento axelvento 1 month ago
RSV: https://s29.q4cdn.com/435878511/files/doc_presentations/2024/Feb/15/rsvvw-2024-p301-additional-analysis-and-cop-oral-presentation_fd-003-sks-1-_rd_final.pdf
👍️0
Vexari Vexari 1 month ago
In the absence of head-to-head clinical trials

Moderna is anticipating approvals of mRNA-1345

In the first half of 2024 Would this not be considered

Predictive programming

Or

Out and out fraud
💩 1 🤡 1
axelvento axelvento 1 month ago
The new analysis included data from more than 36,000 participants, with median vaccine efficacy rates of 63.3% for RSV illnesses with two or more symptoms; 63% for three or more symptoms; and 53.9% against RSV-associated acute respiratory disease at an 8.6-month follow-up.
👍️0
axelvento axelvento 1 month ago
In the absence of head-to-head clinical trials, comparative conclusions regarding the safety and efficacy of mRNA-1345 relative to other RSV vaccines cannot be made. These trials differed in study populations, geographic locations, infection surveillance methods, and case definitions used for RSV.

Moderna is anticipating approvals of mRNA-1345 in the first half of 2024. The Company is encouraged by the strong competitive profile for its RSV vaccine, with robust efficacy data meeting all pre-specified statistical criteria, a well-established safety and tolerability profile, and as the only pre-filled syringe product available at the time of launch.

https://investors.modernatx.com/Statements--Perspectives/Statements--Perspectives-Details/2024/Statement-on-RSVVW-Abstract-on-mRNA-1345-2024-Rk2gVDGnqc/default.aspx
👍️0
Vexari Vexari 1 month ago
What if this whole system

Is rigged

And exactly the opposite

To be true
🤡 1 🥜 1
DewDiligence DewDiligence 1 month ago
The RSV publication is the impetus for the 2-day selloff:

https://finance.yahoo.com/news/moderna-shares-slide-longer-term-152839996.html
👍️0
axelvento axelvento 1 month ago
news imminent -$$$$$

On 13-16 February, 2024

https://resvinet.org/conferences/rsvvw24/

Statement on RSVVW Abstract on mRNA-1345


At an upcoming presentation at the RSVVW’24 conference, Moderna will share follow-up data from its ongoing ConquerRSV Phase 3 study of its investigational RSV vaccine candidate, mRNA-1345.
👍️0
spartex spartex 1 month ago
Guess it gave Papa MRNA stock a 5% haircut for that news.
👍️0
axelvento axelvento 1 month ago
Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln "speculation yesterday"
👍️0
spartex spartex 1 month ago
Pricing on the low end. btw, why did Mod drop $5 bucks yesterday? might retest the 52 week low..........soon.
👍️0
axelvento axelvento 1 month ago
Moderna-backed Metagenomi:
Metagenomi Announces Pricing of Initial Public Offering

The shares are expected to begin trading on the Nasdaq Global Select Market on February 9, 2024 under the ticker symbol “MGX.” The offering is expected to close on February 13, 2024 subject to the satisfaction of customary closing conditions.



https://www.biospace.com/article/releases/metagenomi-announces-pricing-of-initial-public-offering/
👍️0
Vexari Vexari 1 month ago
Where's the she
Anyways, everyone is free to do whatever he wants! As the beef
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com